Knee Steroid Injection and Blood Sugar Signatur

Identifying Variables Associated With Steroid-Induced Hyperglycemia Following Intra-articular Knee Injections Among Diabetic Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04317404

Enrollment

Registered

2020-03-23

Start date

2020-11-01

Completion date

2022-11-30

Last updated

2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Knee Osteoarthritis

Brief summary

A prospective, observational study assessing the relationship between HbA1c level and the post-injection blood glucose signature. Participants will be non-diabetic, pre-diabetic, non-insulin dependent and insulin dependent type 2 diabetic patients who will be receiving a knee steroid injection. All of them will be consented a week prior to the injection, when the CGM sensor will be applied to the back of the upper arm. This will be removed a week after the injection. KOOS survey as well as VAS will be administered. Adverse events (e.g., change in medication or hospitalization) will be monitored throughout the study.

Interventions

DRUG40 mg Triamcinolone acetonide

Unilateral knee steroid injection

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients at the Parkland Outpatient Clinic * Indication for unilateral knee joint steroid injection for the treatment of knee joint osteoarthritis

Exclusion criteria

* Less than 18 years old * HbA1c \> 12.0% * steroid exposure in the 3 months prior to Visit 1 * 3 or more steroid injections in the preceding 12 months * known contraindication to steroid injection (adverse reaction or allergy, active infection, INR \> 3.0) * lack of improvement with prior knee steroid injection * change in diabetic medication regimen in the last 1 month * significant change in diet within the last 1 month * current use of aspirin * allergy to adhesive * planned MRI, XR, or CT during the 2-week study period

Design outcomes

Primary

Measure	Time frame	Description
Post-injection glucose levels	1 week	Blood glucose levels after injection of steroid to the knee

Secondary

Measure	Time frame	Description
Post-injection adverse events	1 week	Adverse events after injection of steroid to the knee
KOOS Knee survey	2 weeks	KOOS Knee survey administered before and after steroid injection to the knee

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026